Skip to main content
Premium Trial:

Request an Annual Quote

Bayer, Foundation Medicine Partner on NGS-Based Companion Diagnostic Test Development

NEW YORK (GenomeWeb) – Bayer and Foundation Medicine said today that they have entered a global collaboration to develop next-generation sequencing companion diagnostics, beginning with a test to identify patients eligible for treatment with larotrectinib (Vitrakvi), a TRK inhibitor now approved in the US for patients with NTRK fusions regardless of tumor type or location.

According to the partners, the agreement further allows for collaboration across multiple other oncology drug candidates and approved therapies developed by Bayer. It also covers Cambridge, Massachusetts-based Foundation's full test portfolio, including FoundationOne CDx, which has been approved by the US Food and Drug Administration for pan-cancer solid tumor CDx applications.

"We are excited to collaborate with Foundation Medicine to develop new companion diagnostics and provide tools to move to a more personalized treatment approach," Robert LaCaze, head of Germany-based Bayer's oncology strategic business unit, said in a statement. "The development of a companion diagnostic for Vitrakvi, and our broader collaboration with Foundation Medicine, is an important step forward toward expanding access to testing and identifying the right treatment options for patients with cancer."

Financial terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.